PerkinElmer Inc., a Waltham provider of equipment and services to support human and environment health, has bought Bedford molecular imaging technology company VisEn Medical Inc.
PerkinElmer (NYSE: PKI) noted in a news release today that the acquisition would help it add preclinical research capabilities, which VisEn has a strong presence in with its fluorescence molecular imaging systems used in cancer, cardiovascular, inflammation, skeletal and pulmonary diseases.
No financial terms of the acquisition were disclosed.
VisEn Medical develops its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic Imaging Systems, which can be help identify biomarkers and therapeutic efficacy in cells. The technology is used by academic research departments, pharmaceutical research organizations, medical imaging facilities, contract research organizations, biologists and radiologists.
VisEn Medical was founded in 2000 by Ralph Weissleder and Kirtland Poss. The privately held company had raised a total of $12.5 million in venture funding, as of the latest report in 2008.
PerkinElmer has made a few acquisitions this year, including its April buyout of Spokane, Wash.-based diagnostic genetic testing firm Signature Genomic Laboratories LLC and its February buy of Washington D.C.-based partner Danaher Corp.’s share of a joint venture in the mass spectrometry business, Inductively Coupled Plasma Mass Spectrometry.
SOURCE
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)